Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Decoy Therapeutics Inc (DCOY)

Decoy Therapeutics Inc (DCOY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,473
  • Shares Outstanding, K 532
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,580 K
  • EBIT $ -5 M
  • EBITDA $ -5 M
  • 60-Month Beta 0.30
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-185.38
  • Growth Rate Est. (year over year) +638.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.94 +9.94%
on 03/31/26
9.09 -28.16%
on 03/10/26
-1.64 (-20.09%)
since 02/27/26
3-Month
5.94 +9.94%
on 03/31/26
16.92 -61.40%
on 01/13/26
-1.36 (-17.20%)
since 12/26/25
52-Week
5.94 +9.94%
on 03/31/26
415.80 -98.43%
on 07/29/25
-148.63 (-95.79%)
since 03/28/25

Most Recent Stories

More News
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

Partnership supported by funding from Google Cloud will increase Decoy's computational peptide design bandwidth by 25-100x

DCOY : 6.53 (-3.39%)
Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

CAMBRIDGE, Mass. , March 5, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ: DCOY), a preclinical-stage biopharmaceutical company that is engineering the next generation of peptide conjugate...

DCOY : 6.53 (-3.39%)
Decoy Therapeutics Joins Webull Corporate Connect Service Platform

-  Connect with the Company on Webull here

DCOY : 6.53 (-3.39%)
JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026

Register for the two-day virtual event here

AKTX : 5.15 (+6.40%)
AIM : 0.5850 (+6.17%)
DCOY : 6.53 (-3.39%)
BULL : 4.80 (+3.67%)
GRI : 2.29 (+1.33%)
MBRX : 2.29 (+2.23%)
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

– Live video webcast on Tuesday, February 10 th at 1:20 PM EST

DCOY : 6.53 (-3.39%)
Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement

Access the "What This Means" segment here

DCOY : 6.53 (-3.39%)
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform

Decoy Therapeutics will use the platform, with funding support from the Gates Foundation, to provide widespread access to peptide-conjugate antivirals from Decoy's IMP 3 ACT™ platform...

DCOY : 6.53 (-3.39%)

Business Summary

Decoy Therapeutics Inc. is a preclinical-stage biotechnology company which target serious unmet medical needs. The Company's initial pipeline is focused on respiratory viruses and GI cancers. Decoy Therapeutics Inc., formerly known as Salarius Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 8.08
2nd Resistance Point 7.54
1st Resistance Point 7.03
Last Price 6.53
1st Support Level 5.98
2nd Support Level 5.44
3rd Support Level 4.93

See More

52-Week High 415.80
Fibonacci 61.8% 259.23
Fibonacci 50% 210.87
Fibonacci 38.2% 162.51
Last Price 6.53
52-Week Low 5.94

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.